4.7 Article

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, Research & Experimental

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice

Chang-Yun Hu et al.

JOURNAL OF CLINICAL INVESTIGATION (2007)

Article Biochemistry & Molecular Biology

Mechanisms of killing by anti-CD20 monoclonal antibodies

Martin J. Glennie et al.

MOLECULAR IMMUNOLOGY (2007)

Article Immunology

Depletion of B cells in murine lupus: Efficacy and resistance

Anupama Ahuja et al.

JOURNAL OF IMMUNOLOGY (2007)

Review Immunology

Antibodies, Fc receptors and cancer

Falk Nimmerjahn et al.

CURRENT OPINION IN IMMUNOLOGY (2007)

Review Immunology

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

JCW Edwards et al.

NATURE REVIEWS IMMUNOLOGY (2006)

Review Immunology

Potent antibody therapeutics by design

PJ Carter

NATURE REVIEWS IMMUNOLOGY (2006)

Article Multidisciplinary Sciences

Role of target geometry in phagocytosis

JA Champion et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

Article Biochemistry & Molecular Biology

The carbohydrate at FcγRIIIa Asn-162 -: an element required for high affinity binding to non-fucosylated IgG glycoforms

C Ferrara et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Article Multidisciplinary Sciences

Divergent immunoglobulin G subclass activity through selective Fc receptor binding

F Nimmerjahn et al.

SCIENCE (2005)

Article Immunology

Complement activation determines the therapeutic activity of rituximab in vivo

N Di Gaetano et al.

JOURNAL OF IMMUNOLOGY (2003)

Article Hematology

Complement activation plays a key role in the side-effects of rituximab treatment

LE van der Kolk et al.

BRITISH JOURNAL OF HAEMATOLOGY (2001)